Tuesday, January 21, 2025 9:25:06 PM
zero82,
So, do you have inside info or are you psychic?? Thanks for advising us and allowing us to know the secrets of the future! 🔮
You do not know whether Merck or BMS or any other company is interested in NWBO, but we do know that BP companies follow clinical trials and they read the peer-reviewed medical literature—they reference and cite clinical data and peer review all the time. We don’t have insider information, but we do have publicly available facts to consider with regard to the overall PD-1 market and all of the BP companies that have or are developing PD-1 drugs.
DC technologies owned by NWBO are being investigated in combo with several BP products at UCLA and at Roswell, including Merck’s pembrolizumab.
Relatively recently, Merck hired an expert in dendritic cell technology (Dr. Butterfield).
Combining PD-1 blockade with dendritic cell vaccines is a relatively new idea. The combo trials at UCLA and Roswell have reached PII, and data are beginning to emerge. PD-1 technology has only been commercially available for 10 years and the drug class is growing along with its demand globally.
⭐️Combo is King!⭐️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357
So, do you have inside info or are you psychic?? Thanks for advising us and allowing us to know the secrets of the future! 🔮
You do not know whether Merck or BMS or any other company is interested in NWBO, but we do know that BP companies follow clinical trials and they read the peer-reviewed medical literature—they reference and cite clinical data and peer review all the time. We don’t have insider information, but we do have publicly available facts to consider with regard to the overall PD-1 market and all of the BP companies that have or are developing PD-1 drugs.
DC technologies owned by NWBO are being investigated in combo with several BP products at UCLA and at Roswell, including Merck’s pembrolizumab.
Relatively recently, Merck hired an expert in dendritic cell technology (Dr. Butterfield).
Combining PD-1 blockade with dendritic cell vaccines is a relatively new idea. The combo trials at UCLA and Roswell have reached PII, and data are beginning to emerge. PD-1 technology has only been commercially available for 10 years and the drug class is growing along with its demand globally.
⭐️Combo is King!⭐️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
